11 July 2024
Graft Polymer (UK)
Plc
("Graft Polymer" or the
"Company")
Filing of two new provisional
patents applications in the US and operational review
update
Graft Polymer (UK) Plc (LON:
GPL), an innovative biopolymer drug
delivery systems development company, is pleased to announce the
filing of two new provisional utility patent applications with the
United States Patent and Trademark Office (the "USPTO"). These
provisional patent applications pertain to the treatment of
substance use disorders ("SUDs") and mental health disorders using
depot drug delivery systems ("DDDS").
Provisional patent applications
SUDs
The first provisional patent
application, titled "Compositions and Methods for Treating
Substance Use Disorders (SUDs) Using Depot Drug Delivery Systems
(DDDS)", addresses the use of DDDS to reduce side effects and
enhance effectiveness of therapeutics used to treat SUDs. Many such
therapeutics require frequent dosing via traditional routes of
administration, and controlling and extending drug release, such as
using biopolymer based depot delivery systems, can potentially
increase patient compliance and potentially improve
outcomes.
Mental health
disorders
The second provisional patent
application, titled "Compositions and Methods for Treating Mental
Health Disorders (MHDS) Using Depot Drug Delivery
Systems (DDDS)", also focuses on the use of
DDDS to reduce side effects and enhance effectiveness of
therapeutics, in particular those used in treating mental health
disorders such as Generalized Anxiety Disorder ("GAD"), Major
Depressive Disorder ("MDD") and Post-Traumatic Stress Disorder
("PTSD"). Similar to treatments for SUDs, current formulations of
these therapeutics often are limited
in their effectiveness and have increased
side effects as a result of gastric and hepatic degradation of the
API, drawbacks which are eliminated by the use of biopolymer based
depot delivery systems, such as for controlled subcutaneous
release.
Strategic
significance
These patent applications aim to
leverage the Company's biopolymer expertise to address significant
unmet medical needs in addiction and mental health therapy,
particularly in the US market. They represents continued progress in developing the Company's
intellectual property ("IP") portfolio. They also signify further
progress in the Company's strategic focus on the healthcare
industry, following the disposal of its industrial plastic
manufacturing unit, Graft Polymer D.O.O. (which was announced on 3
May 2024), and the successful completion of the Company's recent
fundraise
Operational review update
On 6 June 2024, the Company
announced an update on the progress of its operational review,
disclosing that the Board was evaluating a shortlist of five
entities for potential future commercial collaboration in the
Company's area of operation. This operational review is nearing
completion and the Company looks forward to providing further
details in the near term.
Anthony Tennyson, CEO, commented: "We are pleased to announce the filing of these two new
provisional patent applications, which marks another step forward
in our work to leverage the Company's biopolymer expertise for the
potential treatment of substance abuse and mental health disorders.
Our strategic focus on healthcare, underscored by these
applications and our recent corporate actions, demonstrates our
commitment to innovation and growth in this vital
sector."
Enquiries
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive
Director, Email: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive
Director , Email: yifat@graftpolymer.com
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner
(Corporate Finance)
Guy McDougall
(Sales)
+44 (0) 20 3328
5656
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc (LON: GPL) is
an innovative developer of biopolymer drug delivery systems
dedicated to assisting biopharmaceutical companies in enhancing the
effectiveness of their therapeutics. Our proprietary patented
platform, a bioabsorbable self-nanoemulsifying drug delivery system
("SNEDDS"), represents a cutting-edge solution in drug delivery
technology. By integrating active pharmaceutical ingredients
("APIs") into our novel, patented delivery systems, we enable
clients to improve the bioavailability, pharmacokinetics, and
stability of their therapeutics.
www.graftpolymer.com | LinkedIn